Homepage Top Section1

The plant-derived small molecule, tigilanol tiglate targets various solid tumours across multiple species. The drug is being developed as an intratumoural treatment for solid tumours. It has a

Applying Avista’s single-cell adeno-associated virus (AAV) engineering (scAAVengr) platform technology, the partnership intends to develop intravitreal AAV capsids matching a capsid profile defined by Roche. As per the

Discovered and developed by SK Biopharmaceuticals and SK life science, cenobamate is an anti-seizure medication (ASM). It is already approved and available in Europe and the US to treat

The therapy, which has been studied in various Phase I and II clinical trials, demonstrated the potential to amplify T cells across the subsets, improve the immune system,

The company is a joint venture between WuXi Biologics and WuXi STA and provides end-to-end contract research, development, and manufacturing of bioconjugates, such as ADCs. Under the terms

As part of the collaboration, both the companies will conduct research and preclinical development activities together for identifying new monovalent small molecules which regulate target proteins via stabilisation,

As part of the collaboration, the companies will co-develop Bifunctional HER2-Sialidase, which is currently in preclinical development stage, and a second bifunctional sialidase that is to be developed

Rinvoq, which is discovered and developed by AbbVie scientists, is a selective JAK inhibitor that is being studied in many immune-mediated inflammatory diseases. The regulator has recommended the

EP0031 is a potent next generation selective RET inhibitor (SRI) with broad activity against common RET fusions and mutations, like solvent front resistance mutations. It is jointly developed